Advertisement

Production of Antibodies and Antibody Fragments in Escherichia coli

  • Dorothea E. ReillyEmail author
  • Daniel G. Yansura
Protocol
Part of the Springer Protocols Handbooks book series (SPH)

Abstract

Antibodies are an important and growing family of approved therapeutic drugs. Antibody fragments of various types as well as more traditional monoclonal antibodies can be produced using E. coli as the production host. This chapter provides protocols for producing antibody fragments and full-length antibodies in E. coli.

Keywords

Heavy Chain Shake Flask Luria Bertani Antibody Fragment Nonreduced Sample 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We would like to thank Art Huang, James Giulianotti, and Bryant McLaughlin for Western blots.

References

  1. Battersby JE, Snedecor B, Chen C, Champion KM, Riddle L, Vanderlaan M (2001) Affinity-reversed-phase liquid chromatography assay to quantitate recombinant antibodies and antibody fragments in fermentation broth. J Chromatogr A 927:61–76PubMedCrossRefGoogle Scholar
  2. Better M, Chang CP, Robinson RR, Horwitz AH (1988) Escherichia coli secretion of an active chimeric antibody fragment. Science 240:1041–1043PubMedCrossRefGoogle Scholar
  3. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M (1988) Single-chain antigen-binding proteins. Science 242:423–426PubMedCrossRefGoogle Scholar
  4. Cabilly S, Riggs AD, Pande H, Shively JE, Homes WE, Rey M, Perry J, Wetzel R, Heyneker HL (1984) Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli. Proc Natl Acad Sci USA 81:3273–3277PubMedCrossRefGoogle Scholar
  5. Carter P, Kelley RF, Rodriques ML, Snedecor B, Covarrubias M, Velligan MD, Wong WLT, Rowland AM, Kotts CE, Carver ME, Yang M, Bourell JH, Shephard M, Henner D (1992) High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Nat Biotechnol 10:163–167CrossRefGoogle Scholar
  6. Champion KM, Nishihara JC, Joly JC, Arnott D (2001) Similarity of the Escherichia coli proteome upon completion of different biopharmaceutical fermentation processes. Proteomics 1:1133–1148PubMedCrossRefGoogle Scholar
  7. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17:780–783PubMedCrossRefGoogle Scholar
  8. Chen C, Snedecor B, Nishihara JC, Joly JC, McFarland N, Andersen DC, Battersby JE, Champion KM (2004) High–level accumulation of a recombinant antibody fragment in the periplasm of Escherichia coli requires a triple mutant (degP prc spr) host strain. Biotech Bioeng 85:463–474CrossRefGoogle Scholar
  9. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277:35035–35043PubMedCrossRefGoogle Scholar
  10. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, Novotny J, Margolies MN, Ridge RJ, Bruccoleri EH, Crea R, Oppermann H (1988) Protein Engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879–5883PubMedCrossRefGoogle Scholar
  11. Martens T, Schmidt N-O, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144–6152PubMedCrossRefGoogle Scholar
  12. Rodrigues ML, Snedecor B, Chen C, Wong WLT, Garg S, Blank GS, Maneval D, Carter P (1993) Engineering Fab’ fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability. J Immunol 151:6954–6961PubMedGoogle Scholar
  13. Roque ACA, Lowe CR, Taipa MA (2004) Antibodies and genetically engineered related molecules: production and purification. Biotechnol Prog 20:639–654PubMedCrossRefGoogle Scholar
  14. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci USA 105:20167–20172PubMedCrossRefGoogle Scholar
  15. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P, Yansura DG (2002) Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immuno Methods 263:133–147CrossRefGoogle Scholar
  16. Skerra A, Pluckthun A (1988) Assembly of a functional immunoglobulin FV fragment in Escherichia coli. Science 240:1038–1041PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Departments of Early Stage Cell CultureGenentech Inc.South San FranciscoUSA
  2. 2.Antibody EngineeringGenentech IncSouth San FranciscoUSA

Personalised recommendations